PepGen Inc 2025年季度报告

(Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the quarterly period endedMarch 31,2025 OR ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF1934 For the transition period from ___________________ to ___________________Commission File Number:001-41374 PEPGEN INC. (Exact Name of Registrant as Specified in its Charter) 85-3819886(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction of Registrant’s telephone number, including area code: (781)797-0979 Securities registered pursuant to Section 12(b) of the Act: Title of each classTradingSymbol(s)Name of each exchange on which registeredCommon stock, par value $0.0001 per sharePEPGNasdaq Global Select Market Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was requiredto submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 1, 2025, the registrant had32,720,943of common stock, $0.0001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)Condensed Consolidated Statements of Cash Flows (Unaudited)Notes to Condensed Consolidated Financial Statements (Unaudited)Item 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q, or 10-Q, contains express or implied forward-looking statements that are based on ourmanagement’s belief and assumptions and on information currently available to our management and which are made pursuant tothe safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of theSecurities Exchange Act of 1934, as amended, or the Exchange Act. Although we believe that the expectations reflected in theseforward-looking statements are reasonable, these statements relate to future events or our future operational or financialperformance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performanceor achievements to be materially different from any future results, performance or achievements expressed or implied by theseforward-looking statements. Forward-looking statements in this 10-Q include, but are not limited to, statements about: •the initiation, timing, progress, results, and cost of our research and development programs and our current and futurepreclinical studies and clinical trials, including statements regarding the timing of initiation and completion of studies ortrials and related preparatory work, and the period during which the results of our clinical trials will become available;•our ability to efficiently develop our existing product candidates and discover new product candidates;•our ability to successfully manufacture our investigational drug substances and drug product for preclinical use, forclinical trials and on a larger scale for commercial use, if our investigational drug candidates are approved;•our ability to obtain funding for our operations necessary to complete further development and commercialization of